Why Consumers Are Paying Too Much at the Pump
In a recent study, GasBuddy revealed that drivers are prone to overpaying by at least 20 cents per gallon at the pump. This is due to factors such as laziness and procrastination.
In a recent study, GasBuddy revealed that drivers are prone to overpaying by at least 20 cents per gallon at the pump. This is due to factors such as laziness and procrastination.
There is a popular narrative that the retail industry is dying, but is it? A recent report would argue against it, suggesting instead that in fact a retail renaissance is occurring.
CEOs are the captains of their respective ships, weathering the ups and downs that the markets bring. While the horizon looks very bright according to recent research, more captains are abandoning ship than ever.…
Data breaches are perhaps one of the biggest burdens that companies face in 2018. Forget slumping sales or careless ad campaigns. When a company is breached and hackers have all its customers’ information, that’s…
Express released better than expected fiscal fourth-quarter financial results before the markets opened on Wednesday.
Tuesday was a down day for the broad U.S. markets. At first all three major indices started out positive, but over the course of the day each one turned south. Again, most of this…
ETFs have become a growing trend over this past bull market. While many equities posted incredible gains during this time, ETFs were very powerful as well.
The Business Roundtable has released its CEO Outlook Index for the first quarter, and it was very positive considering the recent market volatility.
The Zscaler IPO appears to be growing in popularity, as the firm has increased the number of shares it is offering as well as the price. If this is any indication, we might see…
Amazon.com watched its shares inch forward on Tuesday after a key analyst raised his target on the e-commerce empire.
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares made a solid gain on Tuesday after the company announced interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs).
Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s cystic fibrosis therapy.
Monday was a mixed day for the broad U.S. markets. At first all three major indices started out positive, but over the course of the day they fluctuated between positive and negative, with the…
Although the markets have been subject to a severe amount of volatility recently, the tech sector appears to be the rising tide that stocks are recovering on, and this call on Micron is a…
Goldman Sachs shares are seeing a nice bump on start out the week after a succession plan was confirmed with the investment bank.
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura did not meet the non-inferiority margin of…
Oclaro saw its shares surge early on Monday after it was announced that the company would be acquired by Lumentum.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected bank stocks decreased.
The February 28 short interest data have been compared with the previous report. Short interest decreased in most of these selected semiconductor stocks.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected big oil stocks decreased.